The estimated Net Worth of Peter Salzmann is at least $48.9 Milione dollars as of 21 August 2024. Peter Salzmann owns over 15,068 units of Immunovant Inc stock worth over $29,292,393 and over the last 5 years he sold IMVT stock worth over $10,774,154. In addition, he makes $8,806,830 as Chief Executive Officer e Director at Immunovant Inc.
Sign up
Peter Salzmann IMVT stock SEC Form 4 insiders trading
Peter has made over 25 trades of the Immunovant Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 15,068 units of IMVT stock worth $480,066 on 21 August 2024.
The largest trade he's ever made was selling 125,158 units of Immunovant Inc stock on 7 January 2022 worth over $907,396. On average, Peter trades about 13,760 units every 24 days since 2019. As of 21 August 2024 he still owns at least 1,008,344 units of Immunovant Inc stock.
You can see the complete history of Peter Salzmann stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Peter Salzmann biography
Dr. Peter Salzmann M.D. serves as Chief Executive Officer, Director of the Company. He as served as a member of ISL’s board of directors since October 2019 and is currently the Chief Executive Officer of IMVT Corporation. Since the closing of the Business Combination in December 2019, Dr. Salzmann has served as Immunovant’s Chief Executive Officer and also as a member of the Board. From November 2018 to June 2019, he served as Global Brand Development Leader in Immunology at Eli Lilly and Company, where he designed and executed a comprehensive indication development strategy and oversaw Phase 2 and 3 clinical trial execution. From March 2013 to October 2018, Dr. Salzmann was Head of U.S. Immunology at Eli Lilly, and Managing Director of Lilly Alps from January 2011 to April 2013. From 2008 to 2010, Dr. Salzmann was the Head of Marketing for Eli Lilly China. Dr. Salzmann currently serves as a member of the board of directors of Corbus Pharmaceuticals Holdings, Inc., a publicly traded biotechnology company. Dr. Salzmann earned a B.A. in Chemistry from Northwestern University, an M.D. from University of Chicago’s Pritzker School of Medicine, and an M.B.A. from Stanford University’s Graduate School of Business. The Board believes that Dr. Salzmann’s position as our Chief Executive Officer and his extensive prior experience in the biopharmaceutical industry qualify him to serve as a member of the Board.
What is the salary of Peter Salzmann?
As the Chief Executive Officer e Director of Immunovant Inc, the total compensation of Peter Salzmann at Immunovant Inc is $8,806,830. There are no executives at Immunovant Inc getting paid more.
How old is Peter Salzmann?
Peter Salzmann is 53, he's been the Chief Executive Officer e Director of Immunovant Inc since 2019. There are 8 older and 6 younger executives at Immunovant Inc. The oldest executive at Immunovant Inc is Atul Pande, 65, who is the Independent Director.
What's Peter Salzmann's mailing address?
Peter's mailing address filed with the SEC is C/O IMMUNOVANT, INC., 320 W 37TH STREET, 6TH FLOOR, NEW YORK, NY, 10018.
Insiders trading at Immunovant Inc
Over the last 5 years, insiders at Immunovant Inc have traded over $21,959,710 worth of Immunovant Inc stock and bought 3,433,213 units worth $88,718,319 . The most active insiders traders include Sciences Ltd. Roivant, Peter Salzmann e Julia G. Butchko. On average, Immunovant Inc executives and independent directors trade stock every 14 days with the average trade being worth of $1,150,148. The most recent stock trade was executed by Mark S. Levine on 21 August 2024, trading 3,295 units of IMVT stock currently worth $104,979.
What does Immunovant Inc do?
immunovant, inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. it develops imvt-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in phase iia clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of phase ii clinical trials for the treatment of warm autoimmune hemolytic anemia. the company is headquartered in new york, new york. immunovant, inc. is a subsidiary of roivant sciences ltd.
What does Immunovant Inc's logo look like?
Complete history of Peter Salzmann stock trades at Corbus Pharmaceuticals Inc e Immunovant Inc
Immunovant Inc executives and stock owners
Immunovant Inc executives and other stock owners filed with the SEC include:
-
Peter Salzmann,
Chief Executive Officer, Director -
Pamela Connealy,
Chief Financial Officer -
Dr. Peter Salzmann M.B.A., M.D.,
CEO & Director -
Frank Torti,
Chairman of the Board -
Dr. Julia G. Butchko Ph.D.,
Chief Devel. & Technology Officer -
Andrew Fromkin,
Independent Director -
Douglas Hughes,
Independent Director -
Atul Pande,
Independent Director -
Dr. Frank M. Torti M.B.A., M.D., MBA,
Exec. Chairperson of the Board -
George Migausky,
Independent Director -
Eric Venker,
Director -
W. Bradford Middlekauff,
General Counsel -
Michael Elliott,
Chief Scientific Officer -
Julia Butchko,
Chief Development and Technology Officer -
Dr. William L. Macias M.D., Ph.D.,
Chief Medical Officer -
Lauren Schrier M.B.A.,
VP of Marketing -
Mark S. Levine,
Chief Legal Officer & Corp. Sec. -
Tom Dorney M.B.A., M.S.,
Director of Investor Relations & Strategy -
Eva Renee Barnett M.B.A.,
Chief Financial Officer -
Sciences Holdings, Llc Health,
10% owner -
Robert K Zeldin,
Chief Medical Officer -
Myrtle S Potter,
Director -
Jay S Stout,
Chief Technology Officer -
Rita Jain,
Chief Medical Officer -
William L. Macias,
Chief Medical Officer -
Eva Renee Barnett,
Chief Financial Officer -
Mark S. Levine,
Chief Legal Officer -
Sciences Ltd. Roivant,
-
Michael Geffner,
Chief Medical Officer